Study #2021-0584
Risk-Stratified Adjuvant Therapy: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients with Resectable Colorectal Liver Metastases
MD Anderson Study Status
Enrolling
Treatment Agent
Leucovorin, Capecitabine, 5-FLUOROURACIL, Oxaliplatin, Irinotecan, Bevacizumab
Description
To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Liver Metastases
Study phase:
Phase II
Physician name:
Timothy Newhook
Department:
Surgical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.